{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:25:05Z","timestamp":1786998305737,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014008","name":"Ovarian Cancer Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014561","name":"Juno Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014561","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ygyno.2020.11.009","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T12:53:23Z","timestamp":1605876803000},"page":"427-437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease"],"prefix":"10.1016","volume":"160","author":[{"given":"Christopher B.","family":"Morse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Voillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breanna M.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edison Y.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas M.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Gottardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip D.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin G.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.11.009_bb0005","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0010","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2020.11.009_bb0015","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/15384047.2015.1040960","article-title":"Tumor infiltrating lymphocytes in ovarian cancer","volume":"16","author":"Santoiemma","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0020","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/CCO.0000000000000111","article-title":"Immunotherapy for ovarian cancer: recent advances and perspectives","volume":"26","author":"Zsiros","year":"2014","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0025","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","article-title":"Development of a syngeneic mouse model for events related to ovarian cancer","volume":"21","author":"Roby","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ygyno.2020.11.009_bb0030","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0002-9440(10)64505-1","article-title":"Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma","volume":"161","author":"Zhang","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0035","doi-asserted-by":"crossref","first-page":"16827","DOI":"10.1038\/s41598-017-17119-1","article-title":"CRISPR\/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity","volume":"7","author":"Walton","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0040","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/2326-6066.CIR-19-0258","article-title":"Engineered adoptive T-cell therapy prolongs survival in a preclinical model of advanced-stage ovarian cancer","volume":"7","author":"Anderson","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12967-015-0613-y","article-title":"Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer","volume":"13","author":"Guo","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/jog.13521","article-title":"Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model","volume":"44","author":"Zhu","year":"2018","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0055","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3802\/jgo.2015.26.4.336","article-title":"Role of aggressive surgical cytoreduction in advanced ovarian cancer","volume":"26","author":"Chang","year":"2015","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0060","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ygyno.2016.03.010","article-title":"Characteristics of 10-year survivors of high-grade serous ovarian carcinoma","volume":"141","author":"Dao","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0065","doi-asserted-by":"crossref","first-page":"14342","DOI":"10.1073\/pnas.0804105105","article-title":"Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer","volume":"105","author":"Rabinovich","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0070","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2007.10.035","article-title":"Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer","volume":"108","author":"Greenaway","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0075","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.10121","article-title":"Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer","volume":"7","author":"Greenaway","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2020.11.009_bb0080","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0085","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/bib\/bbv069","article-title":"Gene set analysis approaches for RNA-seq data: performance evaluation and application guideline","volume":"17","author":"Rahmatallah","year":"2016","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0090","first-page":"2","article-title":"An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses","author":"Nunez-Cruz","year":"2010","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089527","article-title":"First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma","volume":"9","author":"Helland","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2020.11.009_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158208","article-title":"The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer","volume":"11","author":"Helland","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2020.11.009_bb0105","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1158\/1078-0432.CCR-12-3847","article-title":"Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin","volume":"19","author":"Remark","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.07.025","article-title":"Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient","volume":"170","author":"Jim\u00e9nez-S\u00e1nchez","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2020.11.009_bb0115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2020.11.009_bb0120","first-page":"517","article-title":"Prognostically relevant gene signatures of high-grade serous ovarian carcinoma","volume":"123","author":"Verhaak","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0125","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.ajpath.2015.12.029","article-title":"Establishment of a novel histopathological classification of high-grade serous ovarian carcinoma correlated with prognostically distinct gene expression subtypes","volume":"186","author":"Murakami","year":"2016","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.12.034","article-title":"Mouse ovarian cancer models recapitulate the human tumor microenvironment and patient response to treatment","volume":"30","author":"Maniati","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0135","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0140","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0145","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0150","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00262-019-02385-x","article-title":"Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature","volume":"68","author":"Hinchcliff","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0155","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-15-2762","article-title":"Tumor-Infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in Ovarian cancer","volume":"22","author":"Kroeger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0160","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0165","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4161\/onci.1.2.18311","article-title":"A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth","volume":"1","author":"Wen","year":"2012","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0170","doi-asserted-by":"crossref","first-page":"815","DOI":"10.21873\/anticanres.13180","article-title":"Baseline tumor size as a predictive and prognostic factor of immune checkpoint inhibitor therapy for non-small cell lung cancer","volume":"39","author":"Katsurada","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2020.11.009_bb0175","article-title":"Tumor burden affects efficacy of combination immunotherapy","volume":"9","year":"2019","journal-title":"Cancer Discov."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820341172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820341172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:54:58Z","timestamp":1758772498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820341172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0090825820341172"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.11.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}